Metrics as of 10/13/2026, 06:37 PM (Berlin time), refresh in progress.
RenovoRx Stock
RenovoRx, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Shaun R. Bagai
- Employees
- 17
- Market cap
- $52 M
- IPO
- 26/08/2021
- Web
- renovorx.com
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing…
RenovoRx stock: price history
1D
-8.0%
1W
-17.3%
1M
-34.7%
6M
+11.7%
YTD
+36.9%
1Y
+6.5%
2Y
+17.3%
5Y
-79.9%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~83% stronger price swings than usual
Ask the agents about RenovoRx
Analyst assessment of RenovoRx
0
STRONG BUY
4
BUY
1
HOLD
0
SELL
0
STRONG SELL
5
TOTAL · Buy
As of: 28/08/2026
RenovoRx stock metrics
P/E
-3.64
P/B
6.06
EV/EBITDA
-3.47
RETURN ON EQUITY
-32.4%
NET MARGIN
-320.2%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.5%
FLOAT SHARES
43,479,865
AVG. DAILY VOLUME (30D)
1,076,957
Insider transactions (SEC)
VOLL MARK
RYAN UNA S
RYAN UNA S
RYAN UNA S
RYAN UNA S
Institutional holders
Comparable stocks
Frequently asked questions about RenovoRx stock
What does RenovoRx do?
RenovoRx, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Shaun R. Bagai, the company employs around 17 people.
The IPO was on 26/08/2021; the stock trades on NASDAQ under the ticker RNXT.
What do analysts say about RenovoRx stock?
5 analysts rate the stock, the consensus is Buy (as of 28/08/2026).
This is an external assessment, not a statement by Market Jury.
When does RenovoRx report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 83% stronger than usual.
Does RenovoRx pay a dividend?
No, RenovoRx currently does not pay a dividend.
Which stocks are comparable to RenovoRx?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get RenovoRx stock analyzed?
Clicking "Analyze stock" lets five strategies assess RenovoRx against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.